| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 30,000 | $235.54 | $7,066,147.21 | -31.3% | +27.0% | +34.3% | |
| Mar 15, 2024 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 20,000 | $60.00 | $1,200,000.00 | -15.0% | +37.7% | +73.8% | |
| Mar 15, 2024 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Sell | 50,000 | $6.00 | $300,000.00 | -4.8% | -54.5% | -53.4% | |
| Mar 14, 2024 | ASRT Assertio Holdings, Inc. | Tyree James L51 | Director | Sell | 10,251 | $1.12 | $11,462.67 | -5.2% | -4.6% | -33.7% | |
| Mar 14, 2024 | NBIX Neurocrine Biosciences Inc | Morrow George J71 | Director | Sell | 40,000 | $139.42 | $5,576,710.00 | -100% | -3.3% | -20.4% | |
| Mar 14, 2024 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 75,000 | $139.38 | $10,453,417.50 | -47.9% | -3.3% | -20.4% | |
| Mar 14, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 30,000 | $240.31 | $7,209,192.46 | -37.6% | +18.4% | +29.0% | |
| Mar 13, 2024 | NBIX Neurocrine Biosciences Inc | Pops Richard F57 | Director | Sell | 23,200 | $140.33 | $3,255,621.20 | -44.0% | -6.1% | -23.1% | |
| Mar 13, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 63,621 | $15.17 | $965,016.05 | -29.2% | +45.8% | +108.6% | |
| Mar 13, 2024 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 62,366 | $33.74 | $2,104,288.68 | -78.4% | -24.4% | -10.1% | |
| Mar 13, 2024 | VTRS Viatris Inc | Mauro Anthony | See Remarks | Sell | 250,000 | $12.09 | $3,023,700.00 | -50.7% | -11.7% | -25.5% | |
| Mar 13, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith49 | Sr. VP, General Counsel &Sec. | Sell | 250 | $66.54 | $16,635.00 | -0.4% | -2.0% | -7.2% | |
| Mar 13, 2024 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 341 | $60.48 | $20,623.68 | -0.5% | +35.8% | +66.4% | |
| Mar 13, 2024 | JNJ Johnson & Johnson | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 8,891 | $162.16 | $1,441,764.56 | -37.1% | -8.9% | +1.2% | |
| Mar 13, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 3,000 | $140.14 | $420,419.40 | -28.6% | -6.1% | -23.1% | |
| Mar 12, 2024 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 3,884 | $32.99 | $128,133.16 | -31.2% | -20.4% | -4.7% | |
| Mar 12, 2024 | UTHR United Therapeutics Corp | Olian Judy D.60 | Director | Sell | 5,000 | $248.20 | $1,241,006.38 | -15.2% | +11.5% | +24.4% | |
| Mar 12, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 30,000 | $247.98 | $7,439,303.04 | -33.3% | +11.5% | +24.4% | |
| Mar 11, 2024 | ANIP Ani Pharmaceuticals Inc | Gassert Chad60 | SVP - Corp. Dev. &Strategy | Sell | 20,000 | $65.81 | $1,316,200.00 | -6.8% | -1.7% | -7.2% | |
| Mar 11, 2024 | ZTS Zoetis Inc. | Reed Willie M55 | Director | Sell | 1,370 | $182.68 | $250,264.75 | -12.1% | -2.5% | -10.4% | |
| Mar 11, 2024 | MRK Merck & Co., Inc. | Merck & Co., Inc. | 10% Owner | Buy | 21,397,205 | $23.00 | $492,135,715.00 | -100.0% | +7.8% | -20.7% | |
| Mar 11, 2024 | NBIX Neurocrine Biosciences Inc | Pops Richard F57 | Director | Sell | 1,800 | $140.04 | $252,078.03 | -3.0% | -2.8% | -22.6% | |
| Mar 11, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 2,000 | $140.03 | $280,052.56 | -11.8% | -2.8% | -22.6% | |
| Mar 11, 2024 | ANIP Ani Pharmaceuticals Inc | Carey Stephen P.55 | SVP &CFO | Sell | 7,787 | $65.55 | $510,437.85 | -4.2% | -1.7% | -7.2% | |
| Mar 11, 2024 | LLY Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, &CAO | Sell | 750 | $753.60 | $565,200.00 | -8.7% | +17.8% | +12.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.